Gamida Cell Ltd [NASDAQ: GMDA] loss -82.74% or -0.28 points to close at $0.06 with a heavy trading volume of 122958035 shares. The company report on March 27, 2024 at 7:00 AM that Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management.
Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge® (omidubicel-onlv).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Gamida Cell to become a private company under ownership of Highbridge following Israeli court approval.
The daily chart for GMDA points out that the company has recorded -93.85% loss over the past six months.
If we look at the average trading volume of 3.08M shares, GMDA reached to a volume of 122958035 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Gamida Cell Ltd [GMDA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GMDA shares is $4.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GMDA stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Alliance Global Partners have made an estimate for Gamida Cell Ltd shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 01, 2021. While these analysts kept the previous recommendation, Evercore ISI raised their target price to Outperform. The new note on the price target was released on July 01, 2020, representing the official price target for Gamida Cell Ltd stock. Previously, the target price had yet another raise to $13, while Piper Sandler analysts kept a Overweight rating on GMDA stock.
The Average True Range (ATR) for Gamida Cell Ltd is set at 0.06, with the Price to Sales ratio for GMDA stock in the period of the last 12 months amounting to 4.41. The Price to Book ratio for the last quarter was 17.41, with the Price to Cash per share for the same quarter was set at 0.37.
Trading performance analysis for GMDA stock
Gamida Cell Ltd [GMDA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -84.26. With this latest performance, GMDA shares dropped by -84.51% in over the last four-week period, additionally sinking by -93.85% over the last 6 months – not to mention a drop of -91.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GMDA stock in for the last two-week period is set at 22.77, with the RSI for the last a single of trading hit 16.95, and the three-weeks RSI is set at 27.49 for Gamida Cell Ltd [GMDA]. The present Moving Average for the last 50 days of trading for this stock 0.3530, while it was recorded at 0.3060 for the last single week of trading, and 0.8181 for the last 200 days.
Gamida Cell Ltd [GMDA]: A deeper dive into fundamental analysis
Gamida Cell Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.09 and a Current Ratio set at 2.16.
Gamida Cell Ltd [GMDA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Gamida Cell Ltd posted -0.3/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -20.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GMDA.
An analysis of Institutional ownership at Gamida Cell Ltd [GMDA]
The top three institutional holders of GMDA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in GMDA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in GMDA stock with ownership which is approximately 5.8325%.
